Wells Fargo’s Longboard Pharmaceuticals, Inc. Common Stock LBPH Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q4 | – | Sell |
-10,035
| Closed | -$334K | – | 7321 |
|
|
2024
Q3 | $334K | Sell |
10,035
-80,119
| -89% | -$2.76M | ﹤0.01% | 4259 |
|
|
2024
Q2 | $2.44M | Buy |
90,154
+81,801
| +979% | +$1.61M | ﹤0.01% | 2820 |
|
|
2024
Q1 | $180K | Buy |
8,353
+3,820
| +84% | +$83.3K | ﹤0.01% | 4535 |
|
|
2023
Q4 | $27.3K | Buy |
4,533
+930
| +26% | +$4.63K | ﹤0.01% | 5518 |
|
|
2023
Q3 | $20K | Sell |
3,603
-2,544
| -41% | -$16.4K | ﹤0.01% | 5598 |
|
|
2023
Q2 | $45.1K | Buy |
6,147
+6,053
| +6,439% | +$45.8K | ﹤0.01% | 5462 |
|
|
2023
Q1 | $377 | Buy |
94
+36
| +62% | +$176 | ﹤0.01% | 6616 |
|
|
2022
Q4 | $189 | Buy |
58
+1
| +2% | +$4 | ﹤0.01% | 6633 |
|
|
2022
Q3 | $0 | Buy |
57
+22
| +63% | +$81 | ﹤0.01% | 7957 |
|
|
2022
Q2 | $0 | Buy |
35
+3
| +9% | +$14 | ﹤0.01% | 8052 |
|
|
2022
Q1 | $0 | Hold |
32
| – | – | ﹤0.01% | 8386 |
|
|
2021
Q4 | $0 | Hold |
32
| – | – | ﹤0.01% | 8340 |
|
|
2021
Q3 | $0 | Sell |
32
-1
| -3% | -$9 | ﹤0.01% | 7980 |
|
|
2021
Q2 | $0 | Buy |
+33
| New | +$329 | ﹤0.01% | 7938 |
|
Wells Fargo's LBPH Position: Q4 2024 in Review
Wells Fargo sold out of Longboard Pharmaceuticals, Inc. Common Stock (LBPH) in Q4 2024, closing a stake of 10,035 shares — an estimated $334K sold.
Wells Fargo first reported a position in LBPH in Q2 2021 and held it in 14 quarters. The position peaked at $2.44M in Q2 2024. 0 funds tracked by Wall St. Rank hold LBPH as of Q4 2024.
- Wells Fargo reported no remaining Longboard Pharmaceuticals, Inc. Common Stock position as of Q4 2024 after selling out during the quarter.
- Wells Fargo sold 10,035 Longboard Pharmaceuticals, Inc. Common Stock shares in Q4 2024, an estimated $334K.
- Wells Fargo first reported a position in Longboard Pharmaceuticals, Inc. Common Stock in Q2 2021 and held it in 14 quarters.
- Wells Fargo's Longboard Pharmaceuticals, Inc. Common Stock position peaked at $2.44M in Q2 2024.
- 0 funds tracked by Wall St. Rank held Longboard Pharmaceuticals, Inc. Common Stock as of Q4 2024.
Based on Wells Fargo's 13F filing for Q4 2024, filed 13 Feb 2025.